Table 4. Associations between baseline characteristics and response in patients treated at/above the RP2D, n=46.
Baseline characteristic | Response rate, n (%) |
---|---|
| |
Age | |
<40 years | 5/12 (41.7%) |
<50 years | 6/18 (33.3%) |
<60 years | 8/32 (25.0%) |
≥60 years | 7/14 (50.0%) |
| |
Secondary disease* | |
Yes | 3/7 (42.9%) |
No | 12/39 (30.8%) |
| |
Duration of CR1 | |
0 months (primary refractory) | 4/18 (22.2%) |
1-6 months | 5/20 (25.0%) |
7-12 months | 3/4 (75.0%) |
>12 months | 3/4 (75.0%) |
| |
Salvage number | |
1 | 11/29 (37.9%) |
2 | 3/12 (25.0%) |
≥3 | 1/5 (20.0%) |
| |
Prior intermediate/high-dose cytarabine | |
Yes | 10/35 (28.6%) |
No | 5/11 (45.5%) |
| |
Prior allogeneic HCT | |
Yes | 5/13 (38.5%) |
No | 10/33 (30.3%) |
| |
Cytogenetic risk | |
Favorable/intermediate | 12/26 (46.2%) |
Adverse | 3/20 (15.0%) |
AML transformed from antecedent hematologic disorder or AML/MDS after prior cytotoxic therapy
Abbreviations: CR, complete remission; HCT, hematopoietic cell transplantation; RP2D, recommended phase 2 dose